WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 270–1., . T-cell prolymphocytic leukaemia. In , , et al. (eds.).
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 276–77., , . Aggressive NK-cell leukaemia. In , , et al. (eds.),
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 158–66., , , , . Introduction and overview of the classification of the lymphoid neoplasms. In , , et al. (eds.),
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 281., , Adult T-cell leukaemia/lymphoma. In , , et al. (eds.),
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 299.. Sézary syndrome. In , , et al. (eds.),
Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sezary syndrome. Am J Clin Pathol 2007;127(4):496–510.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 274–75., , . Chronic lymphoproliferative disorders of NK cells. In , , et al. (eds.),
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98(6):1721–6., , et al.
Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol 2008;80(6):469–76., , .
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 2009;145(2):173–9., , et al.
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004;104(2):328–35., , et al.
Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998;103(2):110–16., , , .
T-cell prolymphocytic leukemia. Expert Rev Anticancer Ther 2009;9(3):365–71.,
Diseases of large granular lymphocytes. Cancer Control 2007;14(2):141–50., .
Perspectives in the treatment of LGL leukemia. Leuk Res 2005;29(2):123–5.,
Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr Opin Hematol 2009;16(1):27–34., .
Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA 2008;105(42):16308–13., , et al.
Large granular lymphocyte leukemia. Oncologist 2006;11(3):263–73.,
DNA microarray analysis of natural killer cell-type lymphoproliferative disease of granular lymphocytes with purified CD3–CD56+ fractions. Leukemia 2004;18(3):556–65., , et al.
Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood 2004;103(9):3431–9., , et al.
Non-Hodgkin Lymphoma. Lippincott Williams & Wilkins; 2009., , , Chronic T-cell and natural killer cell leukemias. In , , , (eds.),
Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56−/+dim chronic natural killer cell large granular lymphocytosis. Am J Pathol 2004;165(4):1117–27., , et al.
Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia 2007;21(5):1060–9., , et al.
Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004;18(12):2002–7., , .
Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood 2003;102(5):1797–805., , et al.
A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol 1999;106(4):960–6., , .
Flow cytometric immunophenotyping of adult T-cell leukemia/lymphoma using CD3 gating. Am J Clin Pathol 2005;124(2):199–204., , et al.
Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology 2009;54(2):214–20., , , .
Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol 2005;78(3):232–9.
Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia 2007;21(8):1752–62., , et al.
Adult T-cell leukemia. Blood Rev 1988;2(4):232–8.
Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977;50(3):481–92., , , , .
Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells. Clin Lab Haematol 2005;27(4):235–41., , et al.
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009;113(26):6528–32., , et al.
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110(6):1713–22., , et al.
CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sezary syndrome by flow cytometry. Cytometry B Clin Cytom 2008;74(3):156–62., , , , .
A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sezary syndrome. Am J Clin Pathol 2006;125(3):364–74., , et al.
Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46(1):95–106., , et al.
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109(11):4655–62., , et al.
Alemtuzumab in Sezary syndrome: efficient but not innocent. Eur J Dermatol 2007;17(6):525–9., , et al.